GlassScriptPhysician profile
Ashley Ann Baggott
NPI 1053856443
$3,520.26
in general payments reported to CMS, 2019-2025
23 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.34 · 2022: $921 · 2023: $690 · 2024: $692 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,450.50 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $464.12 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $291.40 | 2022-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $283.69 | 2022-2025 | Dupixent |
| Pfizer INC. | $241.87 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $160.87 | 2024-2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.25 | 2022-2025 | Xifaxan, Plenvu |
| Genzyme Corporation | $63.15 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $55.07 | 2022-2023 | Ocaliva |
| Boston Scientific Corporation | $49.89 | 2021 | |
| Merck Sharp & Dohme LLC | $43.95 | 2024 | Dificid |
| Celltrion USA INC. | $38.61 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $35.35 | 2025 | Voquezna |
| Ardelyx, INC. | $30.90 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $29.76 | 2023-2024 | Sutab |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.85 | 2025 | Iqirvo |
| Qol Medical, LLC | $24.01 | 2024 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.87 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $21.99 | 2024 | Injectafer |
| Biocon Biologics INC | $21.43 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $20.14 | 2023 | Rebyota |
| Digestive Care, INC. | $18.01 | 2024 | Pertzye |
| Nestle Healthcare Nutrition INC. | $13.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Baggott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.